{
  "docId": "019dd923-622c-750b-8b9d-167a31878e2a",
  "docSlug": "beab175aaed8",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": null,
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 16,
  "pageCount": 197,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 11,
  "notes": "The slide uses a bar chart to show historical revenue concentration and an area chart to show the projected revenue decline of Celgene's portfolio.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9d-167a31878e2a/16",
  "deckHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.52,
        "y": 0.27
      },
      "kind": "chart",
      "text": "Wall Street Estimates for Celgene’s Marketed Products Revenues",
      "attrs": null,
      "subkind": "area-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9ad6531-00b1-42a2-8db7-a0b61d929611",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.04,
        "y": 0.27
      },
      "kind": "chart",
      "text": "Select Blockbuster Drugs – % Revenue Contribution Prior to Loss-of-Exclusivity",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45aeacd5-a039-4f85-9602-0eb90aab8dec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Bristol-Myers is knowingly acquiring a massive small molecule patent cliff, which is, to our knowledge, unprecedented.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db0b0e51-9a71-4086-82c7-909dee334bb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Public company filings, CapitalIQ, Wall Street research. (1) % of total revenues for SINGULAIR, LIPITOR, CRESTOR, CYMBALTA, PLAVIX, and REVLIMID as of 2011, 2010, 2015, 2013, 2011, and 2018, respectively.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62ee89e8-e069-4f0d-9aa3-247431b81065",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "title",
      "text": "A single drug represents 63% of Celgene revenue and is facing an impending patent cliff",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef482818-56d3-4044-926c-daee5b92c385",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Bristol-Myers Is Buying One of the Largest Patent Cliffs in History",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "859b64bb-cb49-4468-9f17-04376bb29c8f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "f0771e02-f80e-4f53-b3e2-563bbc8f85be",
      "evidence": "The slide frames the acquisition as a reckless decision by highlighting the extreme revenue concentration and impending cliff.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 9,
      "beatId": "1be2f377-bde5-4e96-aa19-6d36bdad8e4b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation agitates the problems, providing more details on the acquisition's flaws and potential risks.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 16,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "abb67227-8079-48f4-b3b7-b9f835a4b354",
      "evidence": "The presentation provides a detailed breakdown of the acquisition's valuation, highlighting the potential $30 billion price tag for the pipeline.",
      "position": 1,
      "objective": "How does the acquisition's valuation break down?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.6,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}